Alpha-conotoxins act on postsynaptic membranes, they bind to the nicotinic acetylcholine receptors (nAChR) and thus inhibit them. This toxin blocks mammalian alpha-3-beta-2/CHRNA3-CHRNB2 (IC(50)=7-68 nM) and alpha-7/CHRNA7 (IC(50)=253 nM) nAChRs (PubMed:8068627, PubMed:10545176, PubMed:15929983, PubMed:22024738, PubMed:25101833). It also shows a high inhibition on alpha-6/alpha-3-beta-2-beta-3 (CHRNA6/CHRNA3-CHRNB2-CHRNB3) (IC(50)=11 nM) and a low inhibition on alpha-6-beta-4/CHRNA4-CHRNB4 (IC(50)>500 nM) (PubMed:22024738). It interacts with a hydrophobic pocket between two acetylcholine receptor subunits. In vivo, inhibits Ehrlich carcinoma growth and increase mouse survival (PubMed:32272633). These effects are greatly enhanced when the toxin is applied with the selective 12-lipoxygenase inhibitor baicalein (PubMed:32272633). Expressed by the venom duct. The cysteine framework is I (CC-C-C). Alpha4/7 pattern. The replacement of Ala-10 by a norleucine (A10Nle) produces the more potent analog on alpha-7/CHRNA7 (IC(50)=4.3 nM) and on alpha-3-beta-2/CHRNA3-CHRNB2 (IC(50)=0.7 nM) (PubMed:25101833). This toxin shows no or very weak inhibition on alpha-2-beta-2/CHRNA2-CHRNB2, alpha-3-beta-4/CHRNA3-CHRNB4, alpha-4-beta-2/CHRNA4-CHRNB2 and alpha-6/alpha-3-beta-4 nAChRs. Belongs to the conotoxin A superfamily.